Quick Answer
GOLDENWELL BIOTECH, INC. reported Total Revenue of $139.00 for fiscal year 2024.
GOLDENWELL BIOTECH, INC. — Key Financials by Year
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Total Revenue | $139.00 -92.4% |
$1.8K -96.2% |
$47.8K +199.4% |
$16.0K | $0.00 | $0.00 |
| Revenue (ASC 606) | — | $2.3K -95.1% |
$47.8K +199.4% |
$16.0K | $0.00 | — |
| Net Income | -$131.5K -12.0% |
-$117.4K +88.1% |
-$985.1K -742.1% |
-$117.0K -1749.8% |
-$6.3K -173.6% |
-$2.3K |
| Diluted EPS | $0.00 | $0.00 | — | — | — | — |
| Total Assets | $224.2K -1.7% |
$228.1K -8.2% |
$248.4K -46.1% |
$461.0K +85.5% |
$248.6K +0.8% |
$246.6K |
| Cash and Equivalents | — | — | $46.0K -78.5% |
$213.6K -14.1% |
$248.6K +0.8% |
$246.6K |
| Stockholders Equity | -$47.2K -128.1% |
$168.0K -37.4% |
$268.3K -28.0% |
$372.6K +49.9% |
$248.6K +0.8% |
$246.6K |
| Operating Income | -$123.1K -6.3% |
-$115.8K +88.2% |
-$985.1K -733.0% |
-$118.3K | — | — |
| Gross Profit | $64.00 -90.4% |
$666.00 -97.4% |
$25.2K +200.3% |
$8.4K | $0.00 | $0.00 |
| Shares Outstanding | 99.00M +0.0% |
99.00M +0.0% |
99.00M +8.2% |
91.50M +0.0% |
91.50M +14.4% |
80.00M |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $0.00 | — | — |
| Revenue (ASC 606) | September 30, 2024 | $0.00 | -100.0% | -100.0% |
| Net Income | September 30, 2025 | -$8.0K | -134.6% | -53.0% |
| Diluted EPS | March 31, 2025 | $0.00 | — | — |
| Total Assets | September 30, 2025 | $220.4K | +22.8% | -12.3% |
| Cash and Equivalents | June 30, 2024 | $25.7K | — | -51.7% |
| Stockholders Equity | September 30, 2025 | -$94.8K | -592.9% | -9.2% |
| Operating Income | September 30, 2025 | -$5.9K | +71.9% | -88.6% |
| Gross Profit | September 30, 2025 | $25.0K | — | -33.3% |
| Shares Outstanding | September 30, 2025 | 99.00M | +0.0% | +0.0% |
- GOLDENWELL BIOTECH, INC. reported Total Revenue of $139.00 for fiscal year 2024.
- GOLDENWELL BIOTECH, INC. showed a decrease of -92.4% in Total Revenue compared to the prior fiscal year.
- GOLDENWELL BIOTECH, INC. reported Revenue (ASC 606) of $2.3 thousand for fiscal year 2023.
- GOLDENWELL BIOTECH, INC. showed a decrease of -95.1% in Revenue (ASC 606) compared to the prior fiscal year.
- GOLDENWELL BIOTECH, INC. reported Net Income of -$131.5 thousand for fiscal year 2024.
- GOLDENWELL BIOTECH, INC. showed a decrease of -12.0% in Net Income compared to the prior fiscal year.
- GOLDENWELL BIOTECH, INC. reported Diluted EPS of $0.00 per share for fiscal year 2024.
- GOLDENWELL BIOTECH, INC. reported Total Assets of $224.2 thousand for fiscal year 2024.
- GOLDENWELL BIOTECH, INC. showed a decrease of -1.7% in Total Assets compared to the prior fiscal year.
- GOLDENWELL BIOTECH, INC. reported Cash and Equivalents of $46.0 thousand for fiscal year 2022.
- GOLDENWELL BIOTECH, INC. showed a decrease of -78.5% in Cash and Equivalents compared to the prior fiscal year.
- GOLDENWELL BIOTECH, INC. reported Stockholders Equity of -$47.2 thousand for fiscal year 2024.
- GOLDENWELL BIOTECH, INC. showed a decrease of -156.1% in Stockholders Equity compared to the prior fiscal year.
- GOLDENWELL BIOTECH, INC. reported Operating Income of -$123.1 thousand for fiscal year 2024.
- GOLDENWELL BIOTECH, INC. showed a decrease of -6.3% in Operating Income compared to the prior fiscal year.
- GOLDENWELL BIOTECH, INC. reported Gross Profit of $64.00 for fiscal year 2024.
- GOLDENWELL BIOTECH, INC. showed a decrease of -90.4% in Gross Profit compared to the prior fiscal year.
- GOLDENWELL BIOTECH, INC. reported Shares Outstanding of 99.00 million shares for fiscal year 2024.
- GOLDENWELL BIOTECH, INC. showed an increase of +0.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: